Bispecific Antibody-Armed CIK Cells for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based immunotherapies for cancer treatment are dose-limiting, time-restricted, expensive, and labor-intensive, with limited clinical stability and efficacy, and often result in systemic toxicity.
Innovation Solution
Development of a composition comprising a MSBODY (a bispecific antibody) that binds to a cytotoxic immune cell and a tumor antigen, specifically targeting cytokine-induced killer (CIK) cells to enhance their anti-tumor cytotoxicity by arming them with bispecific antibodies that recognize tumor antigens and immune cells, allowing for more efficient tumor cell targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell-based immunotherapies are used to treat cancer, then anti-tumor efficacy is improved, but systemic toxicity increases and treatment cost increases
Solution Approach 1:
The patent uses bispecific antibodies as intermediaries that bridge CIK cells and tumor cells. The antibodies have dual specificity: one arm binds to CD3 or CD56 on CIK cells, while the other arm binds to tumor-associated antigens. This intermediary mechanism redirects CIK cell cytotoxicity specifically toward tumor cells expressing the target antigen, thereby improving anti-tumor efficacy while reducing off-target systemic toxicity
Solution Approach 2:
The invention applies local quality by modifying CIK cells through arming with bispecific antibodies that confer localized targeting capability. The antibodies are specifically directed against tumor-associated antigens (such as Ep-CAM, Her2, CEA) expressed on tumor cells, enabling CIK cells to selectively recognize and kill tumor cells while sparing normal tissues, thus improving therapeutic index
2Reliability
If cell-based immunotherapies are used to treat cancer, then anti-tumor efficacy is improved, but treatment complexity and labor intensity increase
Solution Approach 1:
The patent implements preliminary action by pre-arming CIK cells with bispecific antibodies ex vivo before administration. The CIK cells are cultured and expanded in advance, then incubated with bispecific antibodies to ensure adequate coating and targeting capability. This preliminary preparation allows the cells to be ready for immediate therapeutic effect upon infusion, simplifying the in vivo process and reducing treatment complexity
Solution Approach 2:
The invention applies universality by developing a platform technology where a single CIK cell product can be armed with different bispecific antibodies targeting various tumor antigens. The same CIK cell preparation methodology and antibody arming protocol can be applied across different cancer types by simply changing the target antigen specificity of the bispecific antibody, thereby reducing overall treatment complexity and enabling broad applicability
3Reliability
If higher concentrations of antibodies are used to enhance targeting, then tumor cell killing is improved, but systemic toxicity increases
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody-to-cell ratio during the arming process to achieve saturation binding of bispecific antibodies on CIK cells. By controlling this parameter, the invention ensures that sufficient antibodies are present to mediate effective tumor cell killing while avoiding excessive antibody concentrations that would lead to systemic toxicity. The optimized ratio maximizes therapeutic effect at minimal effective dose
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly improves the therapeutic efficacy of cell-based immunotherapies by enhancing the targeting and killing of tumor cells with lower antibody concentrations, reducing systemic toxicity, and improving clinical stability and efficiency.
Implementation Method 1
a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the immune cell
Data Source
AI summary
Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.